Literature DB >> 8525390

Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center.

K Neumann1, D J Wallace, C Azen, S Nessim, M Fichman, A L Metzger, J R Klinenberg.   

Abstract

Of 500 patients with systemic lupus erythematosus observed at our center, 150 fulfilled criteria for lupus nephritis. Of these 150 patients, 91% were female, and 67% were white. The mean age of onset was 26.2 years, and the mean follow-up duration was 11.7 years. Biopsies (n = 142) performed on 107 patients showed the following World Health Organization (WHO) class distribution: class I, n = 1; class II, n = 13; class III, n = 19; class IV, n = 69; class V, n = 17; class VI, n = 8; and class not determinable, n = 15. Ninety-five patients were nephrotic. Therapeutic intervention courses given to all patients (n = 356) included parenteral (IV) cyclophosphamide (n = 58), high-dose oral steroids (n = 126), pulse steroids (n = 49), apheresis (n = 39), azathioprine (n = 43), oral cyclophosphamide (n = 5), nitrogen mustard (n = 27), and chlorambucil (n = 6). In addition to examining the course of disease for various subsets, various predictors for fatality and end-stage renal disease (ESRD) were analyzed. Descriptive data for the short-term response to five therapies are provided for the complete patient sample, proliferative disease, and nephrotic syndrome. Twenty patients died, primarily from cardiovascular complications and sepsis, with 97% and 92% 5- and 10-year survival rates, respectively. Twenty-nine were dialyzed, and 11 were transplanted. Risk of ESRD by WHO class at 5 years was as follows: class III, 0%; IV, 9%; V, 16% (P = .04 for class V v other patterns).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8525390     DOI: 10.1016/s0049-0172(95)80017-4

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  16 in total

1.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  A retrospective analysis of clinical presentation of lupus nephritis.

Authors:  Sandeep Singh; Xin J Zhou; Chul Ahn; Ramesh Saxena
Journal:  Am J Med Sci       Date:  2011-12       Impact factor: 2.378

3.  Renal involvement in childhood-onset systemic lupus erythematosus in Egypt.

Authors:  Samia Salah-El-Din Mahmoud; Hafez Mahmoud Bazaraa; Hala Mohamed Lotfy; Doaa Mohamed Abd-El-Aziz
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

4.  Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.

Authors:  Christine Hsieh; Anthony Chang; Daniel Brandt; Riteesha Guttikonda; Tammy O Utset; Marcus R Clark
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-06       Impact factor: 4.794

Review 5.  The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis.

Authors:  Marcus R Clark; Kimberly Trotter; Anthony Chang
Journal:  Semin Nephrol       Date:  2015-09       Impact factor: 5.299

Review 6.  Overview of pathophysiology and treatment of human lupus nephritis.

Authors:  Kimberly Trotter; Marcus R Clark; Vladimir M Liarski
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

7.  Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

Authors:  Abdurahman Saud Al Arfaj; Najma Khalil; Salman Al Saleh
Journal:  Rheumatol Int       Date:  2009-04-21       Impact factor: 2.631

Review 8.  Recent clinical trials in lupus nephritis.

Authors:  Michael M Ward
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670

Review 9.  Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma.

Authors:  Chi Chiu Mok
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

10.  A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis.

Authors:  Hong Wang; Yi-le Ren; Jun Chang; Luo Gu; Ling-Yun Sun
Journal:  Arch Rheumatol       Date:  2017-07-25       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.